Guardian Pharmacy Services, Inc. (GRDN)
| Market Cap | 2.32B +47.8% |
| Revenue (ttm) | 1.46B +13.5% |
| Net Income | 53.07M |
| EPS | 0.84 |
| Shares Out | 63.32M |
| PE Ratio | 43.80 |
| Forward PE | 29.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 506,988 |
| Open | 35.95 |
| Previous Close | 36.27 |
| Day's Range | 35.71 - 37.00 |
| 52-Week Range | 19.17 - 41.36 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 43.17 (+13.63%) |
| Earnings Date | May 6, 2026 |
About GRDN
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company’s individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for GRDN stock is "Strong Buy." The 12-month stock price target is $43.17, which is an increase of 13.63% from the latest price.
News
Guardian Pharmacy Services Transcript: Bank of America Global Healthcare Conference 2026
Delivered a strong quarter, raised annual guidance, and expects high single-digit organic growth, with additional upside from M&A. Maintains a strong balance sheet, leverages scale for profitability, and sees significant opportunity for expansion in the fragmented assisted living pharmacy market.
Guardian Pharmacy price target raised to $43 from $38 at Oppenheimer
Oppenheimer raised the firm’s price target on Guardian Pharmacy (GRDN) to $43 from $38 and keeps an Outperform rating on the shares following the company’s earnings report. Overall, the results…
Guardian Pharmacy files automatic Class A common stock offering
16:45 EDT Guardian Pharmacy (GRDN) files automatic Class A common stock offering
Guardian Pharmacy affirms FY26 revenue view of $1.40B-$1.42B, consensus $1.42B
16:54 EDT Guardian Pharmacy (GRDN) affirms FY26 revenue view of $1.40B-$1.42B, consensus $1.42B
Guardian Pharmacy Services Earnings Call Transcript: Q1 2026
Solid Q1 results with 2% revenue growth and 19% gross profit increase despite IRA headwinds. Updated adjusted EBITDA guidance to $123–$127 million, maintained revenue outlook, and continued robust M&A activity.
Guardian Pharmacy Services Reports First Quarter 2026 Financial Results; Updates Full-Year Guidance
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation's leading long-term care ("LTC") pharmacy services companies, announced today its financial results for the f...
Guardian Pharmacy initiated with a Buy at BofA
BofA analyst Allen Lutz initiated coverage of Guardian Pharmacy (GRDN) with a Buy rating and $42 price target The firm sees “a long path of elevated growth” given Guardian’s strong…
Guardian Pharmacy Services, Inc. to Participate in the Bank of America 2026 Healthcare Conference
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) will be attending the Bank of America 2026 Healthcare Conference in Las Vegas on Wednesday, May 13, 2026. Fred Burke, President ...
Guardian Pharmacy Services, Inc. to Report First Quarter 2026 Financial Results and Host Conference Call
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that it will release first quarter 2026 financial results after market close on Wednesday, May 6, 2026. Manageme...
Guardian Pharmacy price target raised to $43 from $38 at Truist
Truist analyst David MacDonald raised the firm’s price target on Guardian Pharmacy (GRDN) to $43 from $38 and keeps a Buy rating on the shares as part of a broader…
Guardian Pharmacy initiated with a Buy at Jefferies
Jefferies initiated coverage of Guardian Pharmacy (GRDN) with a Buy rating and $44 price target The company is positioned post annual 12%-16% EBITDA growth given the secular growth in the…
Guardian Pharmacy prices 6M shares at $31.00 in upsized public offering
Guardian Pharmacy (GRDN) Services announced the pricing of its upsized underwritten public offering of 6,000,000 shares of its Class A common stock at a public offering price of $31.00 per…
Guardian Pharmacy Services Announces Pricing of Upsized Underwritten Public Offering of Class A Common Stock
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (“Guardian”) (NYSE: GRDN) today announced the pricing of its upsized underwritten public offering (the “Offering”) of 6,000,000 shares of its...
Guardian Pharmacy announces 5M Class A common stock offering
Guardian Pharmacy (GRDN) Services announced the launch of a proposed underwritten public offering of 5M shares of its Class A common stock, consisting of 3.98M shares being offered by certain…
Guardian Pharmacy Services Announces Launch of Underwritten Public Offering of Class A Common Stock
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (“Guardian”) (NYSE: GRDN) today announced the launch of a proposed underwritten public offering (the “Offering”) of 5,000,000 shares of its C...
Guardian Pharmacy Services Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Strong Q4 momentum was driven by vaccine clinics, acquisitions, and operational optimization. Guidance was raised on robust vaccine performance, with IRA headwinds expected to diminish. Growth is supported by demographic trends, M&A, and innovative clinical programs, while strong cash flow enables continued expansion.
Guardian Pharmacy price target raised to $38 from $35 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised the firm’s price target on Guardian Pharmacy (GRDN) to $38 from $35 and keeps an Outperform rating on the shares following quarterly results. The firm…
Guardian Pharmacy price target raised to $38 from $34 at Truist
Truist analyst David MacDonald raised the firm’s price target on Guardian Pharmacy (GRDN) to $38 from $34 and keeps a Buy rating on the shares after its better-than-expected Q4 results…
Guardian Pharmacy Services Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 results exceeded expectations, with 18% revenue growth and 27% adjusted EBITDA growth year-over-year. Raised 2026 EBITDA guidance to $120–$124 million, maintaining strong cash flow and robust M&A pipeline amid industry changes.
Guardian Pharmacy Services Reports Fourth Quarter and Full Year 2025 Financial Results; Raises 2026 Adjusted EBITDA Guidance
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation's leading long-term care ("LTC") pharmacy services companies, announced today its financial results for the f...
Guardian Pharmacy Services, Inc. to Participate in Upcoming Oppenheimer Healthcare MedTech & Services Conference
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that the company will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference. Fred ...
Guardian Pharmacy Services Transcript: 47th Annual Raymond James Institutional Investor Conference
A leading assisted living pharmacy provider is leveraging organic growth, disciplined M&A, and a tech-enabled service model to expand its 13% market share. Strong financials, high adoption rates, and proactive regulatory engagement position it for continued growth amid favorable demographic trends.
Guardian Pharmacy Services, Inc. to Participate in Upcoming Raymond James Institutional Investor Conference
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that the company will present at the Raymond James Institutional Investors Conference in Orlando, Florida on Mon...
Guardian Pharmacy Services, Inc., to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that it will release fourth quarter and full-year 2025 financial results after market close on Wednesday, March ...
Guardian Pharmacy Services Transcript: 44th Annual J.P. Morgan Healthcare Conference
A leading long-term care pharmacy provider for assisted living facilities, the company leverages technology, data analytics, and a disciplined growth strategy to expand its 13% market share. Despite regulatory headwinds from the Inflation Reduction Act, it projects continued EBITDA growth and strong cash flow, supported by organic expansion and targeted M&A.